
January to March 2026
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| PEMBROLIZUMAB | $161,570,462 | 18,983 |
| DUPILUMAB | $154,165,205 | 89,778 |
| ELEXACAFTOR + TEZACAFTOR + IVACAFTOR (&) IVACAFTOR | $153,572,105 | 7,560 |
| NIVOLUMAB | $108,878,000 | 15,298 |
| UPADACITINIB | $93,332,128 | 62,817 |
| SEMAGLUTIDE | $92,460,242 | 768,724 |
| DARATUMUMAB | $86,813,337 | 12,173 |
| AFLIBERCEPT | $76,401,392 | 121,758 |
| APIXABAN | $71,040,024 | 1,115,551 |
| OCRELIZUMAB | $64,746,164 | 3,944 |
| TAFAMIDIS | $61,971,208 | 6,191 |
| DENOSUMAB | $58,118,416 | 314,684 |
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| ROSUVASTATIN | $25,530,850 | 4,003,316 |
| PANTOPRAZOLE | $17,539,120 | 2,625,444 |
| ATORVASTATIN | $18,105,773 | 2,564,716 |
| ESOMEPRAZOLE | $13,710,802 | 1,795,708 |
| ESCITALOPRAM | $6,249,509 | 1,577,819 |
| SERTRALINE | $6,459,826 | 1,532,305 |
| PERINDOPRIL | $9,275,648 | 1,469,464 |
| METFORMIN | $9,036,917 | 1,395,662 |
| CEFALEXIN | $6,085,996 | 1,268,732 |
| AMLODIPINE | $7,023,288 | 1,121,990 |
| APIXABAN | $71,040,024 | 1,115,551 |
| TELMISARTAN | $5,926,673 | 991,611 |
| Contributor | Contribution Dollars |
|---|---|
| Australian Government | $4,839,236,882 |
| Patients | $993,227,034 |